Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Cytopenia 1 Advanced Cancer 1

Interventions

Nivolumab 13 Surveys and Questionnaires 6 Ipilimumab 6 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 Sirolimus 4 Pemetrexed 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 ARRY-334543 4 temsirolimus 3 relatlimab 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 regorafenib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Doxorubicin 2 Dasatinib 2 Cyclophosphamide 2 vorolanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Cancer × IDO-1 inhibitor LY3381916 × Clear all

NCT03335540 2022-09-26

ADVISE

Bristol-Myers Squibb

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡